Skip to main content
CRYO CELL INTERNATIONAL INC logo

CRYO CELL INTERNATIONAL INC — Investor Relations & Filings

Ticker · CCEL ISIN · US2288951088 LEI · 254900AQWFD6AR2J7Z30 US Human health and social work activities
Filings indexed 897 across all filing types
Latest filing 2022-02-14 Major Shareholding Noti…
Country US United States of America
Listing US CCEL

About CRYO CELL INTERNATIONAL INC

https://www.cryo-cell.com/

Cryo-Cell International, Inc. is a biotechnology company specializing in cellular processing and cryogenic storage. Established in 1989 as the world's first private cord blood bank, the company's primary service is the collection, processing, and long-term preservation of stem cells from umbilical cord blood and cord tissue. These services are offered to families for potential future use in treating a wide range of medical conditions. The company is focused on providing high-quality cryopreservation services and contributing to the advancement of regenerative medicine through its support of research and clinical applications.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-14 English
FORM 4/A SUBMISSION
Director's Dealing
2022-02-08 English
FORM 4/A SUBMISSION
Director's Dealing
2022-02-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses a notice from NASDAQ regarding non-compliance with listing rules due to the audit committee composition, and the company's plan to regain compliance within a cure period. This is a regulatory announcement about a listing issue, not a full financial report, earnings release, or management discussion. The document length is 3744 characters, which is relatively short and consistent with a regulatory filing rather than a detailed report. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Delisting Announcement (DLST) since the stock is not being delisted yet, but rather a notice of non-compliance and cure period.
2022-01-25 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.